血清同型半胱氨酸作为肿瘤标志物的初步探讨
Initial investigation of serum homocysteine as cancer biomarker
目的 检测同型半胱氨酸在多种常见恶性肿瘤患者血清中的表达水平,并初步研究其作为肿瘤标志物的可能性.方法 选择首都医科大学附属北京友谊医院外科明确诊断的180例恶性肿瘤患者和30例正常健康体检者(对照组),检测其空腹血清同型半胱氨酸和肿瘤标志物(CEA、AFP、CA125、CA199)水平,并按照临床上使用的cutoff值,将同型半胱氨酸的结果与肿瘤标志物的结果比较.结果 对照组血清同型半胱氨酸为(11.40±3.13) μmol/L,恶性肿瘤患者血清同型半胱氨酸均升高[(13.89±4.95) μmol/L～(21.40±9.38) μmol/L],平均(17.01 ±9.32) μmol/L差异均有统计学意义(P＜0.05).结论 与另外4种肿瘤标志物(CEA、AFP、CA125、CA199)相比,血清同型半胱氨酸在肺癌、乳腺癌、食管癌中具有更高的阳性预测率.血清同型半胱氨酸水平在肿瘤患者血清中升高具有普遍性,并且按照临床上使用的cutoff值,可以将其用作为肺癌、乳腺癌和食管癌的肿瘤标志物.
更多
Objective To study the expression of homocysteine in serum of patients with common malignant tumor,and initially investigate the possibility of serum homocysteine as cancer biomarker.Methods Expression levels of homocysteine and caner biomarkers (CEA,AFP,CA125,CA199) in serum of 180 patients with established malignant tumor and 30 healthy controls (control) were measured,the results of homocysteine were compared with that of the cancer biomarkers based on the cutoff value used in clinic.Results The expression levels of homocysteine was significantly higher in patients with malignant tumor than in controls [(13.89 ± 4.95) μmol/L-(21.40 ± 9.38) μ mol/L vs (11.40 ± 3.13) μmol/L,P ＜ 0.05)].Conclusions The positive predictive rate of homocysteine is higher than the four kind of cancer biomarkers in lung cancer,breast cancer,esophageal cancer.The increase of homocysteine in tumors may be universal,and Homocysteine may be used as cancer biomarker in lung cancer,breast cancer and esophageal cancer.